Table 5 Prognostic value of Bcl-2 expression estimated by multivariate analysis in 76 triple-negative basal-like FMCs
| Â | Categories | p | HR | 95%-CI |
|---|---|---|---|---|
Overall survival | ||||
 Bcl-2 expression | Bcl-2+ versus Bcl-2– | 0.047 | 0.53 | 0.28–0.99 |
 WHO stage | Stages I–II versus III–IV | 0.004 | 2.13 | 1.28–3.54 |
Cancer-specific survival | ||||
 Bcl-2 expression | Bcl-2+ versus Bcl-2– | 0.047 | 0.45 | 0.21–0.99 |
 Pathologic nodal stage | pNX versus pN0 | 0.158 | 2.22 | 0.74–6.72 |
pN+ versus pN0 | 0.004 | 4.66 | 1.63–13.34 | |